Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.

Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM.

Cancer Chemother Pharmacol. 2009 May;63(6):1147-56. doi: 10.1007/s00280-008-0890-8.

2.

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T.

Invest New Drugs. 2013 Jun;31(3):685-95. doi: 10.1007/s10637-012-9863-1.

3.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

4.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5.

5.

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.

LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J.

Cancer Chemother Pharmacol. 2008 Dec;63(1):109-15. doi: 10.1007/s00280-008-0719-5.

PMID:
18322686
6.

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.

Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.

Leuk Res. 2006 Jul;30(7):813-22.

PMID:
16478631
7.

Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.

Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V.

Oncology. 2002;62(3):216-22.

PMID:
12065868
8.
9.

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.

Oncology. 2011;80(1-2):50-6. doi: 10.1159/000327739.

PMID:
21625179
11.

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.

Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ.

Cancer Chemother Pharmacol. 2008 Dec;63(1):99-107. doi: 10.1007/s00280-008-0716-8.

12.

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.

Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA.

Cancer Chemother Pharmacol. 2001 Aug;48(2):95-103.

PMID:
11561784
13.

A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.

Maltezos E, Amarantidis K, Trichas M, Vasiliadis M, Toromanidou M, Chatzaki E, Karayiannakis A, Tsaroucha A, Romanidis K, Kakolyris S.

Oncology. 2005;69(6):463-9.

PMID:
16374040
14.

An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.

Tambaro R, Greggi S, Iaffaioli RV, Rossi A, Pisano C, Manzione L, Ferrari E, Di Maio M, Iodice F, Casella G, Laurelli G, Pignata S.

Ann Oncol. 2003 Sep;14(9):1406-11.

PMID:
12954580
15.

Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.

Kouroussis Ch, Androulakis N, Vamvakas L, Kalykaki A, Spiridonakou S, Kentepozidis N, Saridaki Z, Xiropoulou E, Georgoulias V.

Oncology. 2005;69(3):202-7.

PMID:
16127289
16.

Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.

Briasoulis E, Pentheroudakis G, Karavasilis V, Tzamakou E, Rammou D, Pavlidis N.

Ann Oncol. 2004 Oct;15(10):1566-73.

PMID:
15367419
18.
19.

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.

Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD.

Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. doi: 10.1007/s00280-010-1250-z.

20.

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ.

Anticancer Drugs. 2015 Aug;26(7):785-92. doi: 10.1097/CAD.0000000000000250.

Supplemental Content

Support Center